Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

VLON
Vallon Pharmaceuticals Inc. Common Stock
stock NASDAQ

Inactive
Apr 21, 2023
12.00USD-13.043%(-1.80)37,116
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-13.80)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
08:35AM EST  Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top   GlobeNewswire Inc
Jan 18, 2022
08:16AM EST  Vallon Pharmaceuticals Presents New Data From Adult Stimulant Abuse Pattern Survey At APSARD 2022 Annual Conference   Benzinga
08:05AM EST  -Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall,are the most commonlyabused preparation of prescription stimulants   GlobeNewswire Inc
Jan 4, 2022
08:05AM EST  Vallon Pharmaceuticals to Present at the H.C. Wainwright   GlobeNewswire Inc
Dec 23, 2021
08:06AM EST  UPDATE: Vallon Pharma Sees Topline Results From SEAL Study Q1'22   Benzinga
08:06AM EST  Vallon Pharma Reports Achieved Last Patient Last Visit In SEAL Study For Its ADAIR   Benzinga
08:05AM EST  Vallon Pharmaceuticals Announces Achievement of Last Patient Last   GlobeNewswire Inc
Nov 24, 2021
10:23AM EST  Mid-Morning Market Update: Markets Open Lower; Deere Earnings Top Views   Benzinga
Nov 22, 2021
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021   Benzinga
06:26AM EST  HC Wainwright & Co. Initiates Coverage On Vallon Pharmaceuticals with Buy Rating, Announces Price Target of $12   Benzinga
Nov 12, 2021
08:17AM EST  Vallon Pharmaceuticals Q3 2021 Net Loss $(1.3)M   Benzinga
08:05AM EST  - Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022   GlobeNewswire Inc
Nov 11, 2021
08:05AM EST  -Live moderated video webcast discussion among members of management and ADHDand abuse expert, Stephen V. Faraone, Ph.D.,on Thursday, November 18th at 300 PM ET   GlobeNewswire Inc
Nov 10, 2021
08:35AM EST  - Live video webcast presentation on Monday, November 15th at 8:30 am ET   GlobeNewswire Inc
Nov 1, 2021
08:35AM EDT  -Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication   GlobeNewswire Inc
Oct 12, 2021
08:46AM EDT  Vallon Pharma Offers Update On Progress Of Its Development Programs, ADAIR, ADMIR   Benzinga
08:35AM EDT  -Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study   GlobeNewswire Inc
Sep 14, 2021
08:14AM EDT  Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board   Benzinga
08:05AM EDT  - Inaugural appointments includeglobally renowned leaders and experts onattention-deficit/hyperactivity disorder (ADHD)and stimulant abuse   GlobeNewswire Inc
Aug 11, 2021
08:05AM EDT  Live video webcast with David Baker, President and CEO of Vallon,on Wednesday, August18th1230 PM ET   GlobeNewswire Inc
Aug 10, 2021
08:10AM EDT  Vallon Pharmaceuticals Q2 Net Loss $2.3M   Benzinga
08:05AM EDT  - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021   GlobeNewswire Inc
Jul 13, 2021
08:11AM EDT  Vallon Pharmaceuticals Announces Issuance Of New European Patent Covering Method Of Use, Composition OF Matter For ADAIR   Benzinga
08:07AM EDT  -Patent bolsters intellectual property protection as Companys partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
09:15AM EDT  -Company remains on track to report pivotal data from lead program, ADAIR,in second half 2021   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 11, 2021
09:15AM EDT  Vallon Pharma Names Leanne Kelly CFO   Benzinga
09:05AM EDT  -Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm   GlobeNewswire Inc
May 7, 2021
08:05AM EDT  Live video webcast with David Baker, President and CEO of Vallonon Tuesday, May 18, 2021at 4:15 PM ET   GlobeNewswire Inc
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 26, 2021
09:05AM EDT  David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29that 10:30 AM ET   GlobeNewswire Inc
Apr 13, 2021
08:08AM EDT  Vallon Pharmaceuticals Provides Clinical Update On ADAIR Program   Benzinga
08:05AM EDT  - Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines in the treatment of ADHD, a ~$9 billion U.S. market1   GlobeNewswire Inc
Apr 6, 2021
04:55PM EDT  Vallon Pharmaceuticals Shares Move Higher; Co Tweets '$VLON is leveraging well-established study approaches in the evaluation of our lead #abusedeterrent program, #ADAIR. #ADHD #StimulantAbuse'   Benzinga
Mar 29, 2021
08:07AM EDT  Vallon Pharmaceuticals FY20 Net Loss ~$4.8M, Cash, Cash Equivalents ~$109K   Benzinga
08:05AM EDT  Vallon Pharmaceuticals Reports Full Year 2020 Financial Results   GlobeNewswire Inc
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Mar 3, 2021
08:35AM EST  Vallon Pharmaceuticals to Present at the H.C. Wainwright Global   GlobeNewswire Inc
Feb 24, 2021
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
Feb 23, 2021
09:05AM EST  - Accomplished executive leader with more than 30 years of experience in finance and operations   GlobeNewswire Inc
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 16, 2021
06:20AM EST  SALMON Pharma GmbH Reported 20.5% Stake in Vallon Pharmaceuticals in 13D Filing   Benzinga
Feb 12, 2021
03:30PM EST  Vallon Pharmaceuticals Announces Closing of Initial Public Offering   GlobeNewswire Inc
Feb 10, 2021
10:57AM EST  Vallon Pharmaceuticals Shares Open For Trade At $9.01; IPO Priced At $8/Share   Benzinga
10:13AM EST  Vallon Pharmaceuticals Shares Will Open For Trade At 10:35 a.m. EST, Expected To Open For Trade After 10:45 a.m. EST; IPO Priced At $8/Share   Benzinga
Feb 9, 2021
10:24PM EST  Vallon Pharmaceuticals Announces Pricing of Initial Public Offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC